🇺🇸 fluorothymidine F 18 in United States

6 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 6

Most-reported reactions

1. Aspartate Aminotransferase Increased — 1 report (16.67%)
2. Blood Lactate Dehydrogenase Increased — 1 report (16.67%)
3. Drug Ineffective — 1 report (16.67%)
4. Interstitial Lung Disease — 1 report (16.67%)
5. Lymphocyte Percentage Decreased — 1 report (16.67%)
6. Pneumonia — 1 report (16.67%)

Source database →

Frequently asked questions

Is fluorothymidine F 18 approved in United States?

fluorothymidine F 18 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for fluorothymidine F 18 in United States?

John M. Buatti is the originator. The local marketing authorisation holder may differ — check the official source linked above.